IGN311

DB04988

biotech investigational

Deskripsi

IGN311 is a humanized monoclonal antibody (mab) against the Lewis Y carbohydrate antigen, a blood-group-related oligosaccharide.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

372 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of IGN311.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of IGN311.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of IGN311.
Estrone Estrone may increase the thrombogenic activities of IGN311.
Estradiol Estradiol may increase the thrombogenic activities of IGN311.
Dienestrol Dienestrol may increase the thrombogenic activities of IGN311.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of IGN311.
Mestranol Mestranol may increase the thrombogenic activities of IGN311.
Estriol Estriol may increase the thrombogenic activities of IGN311.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of IGN311.
Quinestrol Quinestrol may increase the thrombogenic activities of IGN311.
Hexestrol Hexestrol may increase the thrombogenic activities of IGN311.
Tibolone Tibolone may increase the thrombogenic activities of IGN311.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of IGN311.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of IGN311.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of IGN311.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of IGN311.
Zeranol Zeranol may increase the thrombogenic activities of IGN311.
Equol Equol may increase the thrombogenic activities of IGN311.
Promestriene Promestriene may increase the thrombogenic activities of IGN311.
Methallenestril Methallenestril may increase the thrombogenic activities of IGN311.
Epimestrol Epimestrol may increase the thrombogenic activities of IGN311.
Moxestrol Moxestrol may increase the thrombogenic activities of IGN311.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of IGN311.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of IGN311.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of IGN311.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of IGN311.
Biochanin A Biochanin A may increase the thrombogenic activities of IGN311.
Formononetin Formononetin may increase the thrombogenic activities of IGN311.
Estetrol Estetrol may increase the thrombogenic activities of IGN311.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with IGN311.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with IGN311.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with IGN311.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with IGN311.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with IGN311.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with IGN311.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with IGN311.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with IGN311.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with IGN311.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with IGN311.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with IGN311.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with IGN311.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with IGN311.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with IGN311.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with IGN311.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with IGN311.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with IGN311.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with IGN311.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with IGN311.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with IGN311.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with IGN311.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with IGN311.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with IGN311.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with IGN311.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with IGN311.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with IGN311.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with IGN311.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with IGN311.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with IGN311.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with IGN311.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with IGN311.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with IGN311.
Oregovomab The risk or severity of adverse effects can be increased when Oregovomab is combined with IGN311.
Adecatumumab The risk or severity of adverse effects can be increased when IGN311 is combined with Adecatumumab.
Labetuzumab The risk or severity of adverse effects can be increased when IGN311 is combined with Labetuzumab.
Matuzumab The risk or severity of adverse effects can be increased when IGN311 is combined with Matuzumab.
Fontolizumab The risk or severity of adverse effects can be increased when IGN311 is combined with Fontolizumab.
Bavituximab The risk or severity of adverse effects can be increased when IGN311 is combined with Bavituximab.
CR002 The risk or severity of adverse effects can be increased when IGN311 is combined with CR002.
Rozrolimupab The risk or severity of adverse effects can be increased when IGN311 is combined with Rozrolimupab.
Girentuximab The risk or severity of adverse effects can be increased when IGN311 is combined with Girentuximab.
Obiltoxaximab The risk or severity of adverse effects can be increased when IGN311 is combined with Obiltoxaximab.
XTL-001 The risk or severity of adverse effects can be increased when IGN311 is combined with XTL-001.
NAV 1800 The risk or severity of adverse effects can be increased when IGN311 is combined with NAV 1800.
Briakinumab The risk or severity of adverse effects can be increased when IGN311 is combined with Briakinumab.
Otelixizumab The risk or severity of adverse effects can be increased when IGN311 is combined with Otelixizumab.
AMG 108 The risk or severity of adverse effects can be increased when IGN311 is combined with AMG 108.
Iratumumab The risk or severity of adverse effects can be increased when IGN311 is combined with Iratumumab.
Enokizumab The risk or severity of adverse effects can be increased when IGN311 is combined with Enokizumab.
Ramucirumab The risk or severity of adverse effects can be increased when IGN311 is combined with Ramucirumab.
Farletuzumab The risk or severity of adverse effects can be increased when IGN311 is combined with Farletuzumab.
Veltuzumab The risk or severity of adverse effects can be increased when IGN311 is combined with Veltuzumab.
Ustekinumab The risk or severity of adverse effects can be increased when IGN311 is combined with Ustekinumab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when IGN311 is combined with Trastuzumab emtansine.
PRO-542 The risk or severity of adverse effects can be increased when IGN311 is combined with PRO-542.
TNX-901 The risk or severity of adverse effects can be increased when IGN311 is combined with TNX-901.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when IGN311 is combined with Inotuzumab ozogamicin.
RI 624 The risk or severity of adverse effects can be increased when IGN311 is combined with RI 624.
Stamulumab The risk or severity of adverse effects can be increased when IGN311 is combined with MYO-029.
CT-011 The risk or severity of adverse effects can be increased when IGN311 is combined with CT-011.
Leronlimab The risk or severity of adverse effects can be increased when IGN311 is combined with Leronlimab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when IGN311 is combined with Glembatumumab vedotin.
Olaratumab The risk or severity of adverse effects can be increased when IGN311 is combined with Olaratumab.
IPH 2101 The risk or severity of adverse effects can be increased when IGN311 is combined with IPH 2101.
TB-402 The risk or severity of adverse effects can be increased when IGN311 is combined with TB-402.
Caplacizumab The risk or severity of adverse effects can be increased when IGN311 is combined with Caplacizumab.
IMC-1C11 The risk or severity of adverse effects can be increased when IGN311 is combined with IMC-1C11.
Eldelumab The risk or severity of adverse effects can be increased when IGN311 is combined with Eldelumab.
Lumiliximab The risk or severity of adverse effects can be increased when IGN311 is combined with Lumiliximab.
Canakinumab The risk or severity of adverse effects can be increased when IGN311 is combined with Canakinumab.

Target Protein

Epidermal growth factor receptor EGFR
Receptor tyrosine-protein kinase erbB-2 ERBB2

Referensi & Sumber

Artikel (PubMed)
  • PMID: 14871842
    Klinger M, Farhan H, Just H, Drobny H, Himmler G, Loibner H, Mudde GC, Freissmuth M, Sexl V: Antibodies directed against Lewis-Y antigen inhibit signaling of Lewis-Y modified ErbB receptors. Cancer Res. 2004 Feb 1;64(3):1087-93.
  • PMID: 16370394
    Kristeleit H: IGN-311. Igeneon. Curr Opin Investig Drugs. 2005 Dec;6(12):1272-9.
  • PMID: 17296336
    Antes B, Amon S, Rizzi A, Wiederkum S, Kainer M, Szolar O, Fido M, Kircheis R, Nechansky A: Analysis of lysine clipping of a humanized Lewis-Y specific IgG antibody and its relation to Fc-mediated effector function. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 1;852(1-2):250-6. Epub 2007 Jan 26.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul